Progressive Multiple Sclerosis

• EMA approval · 2026-08-21
  EMA Authorised: Cenrifki (tolebrutinib) — Sanofi Winthrop Industrie

  Cenrifki (tolebrutinib) has been authorised by the EMA for therapeutic use in multiple sclerosis, including chronic progressive forms.

• EMA approval · 2026-06-25
  EMA Authorised: Cenrifki (tolebrutinib) — Sanofi Winthrop Industrie

  Cenrifki (tolebrutinib) has been authorised in the EU for multiple sclerosis, including chronic progressive forms.

• FDA approval · 2025-08-21
  FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for MAYZENT (siponimod) to expand its indication to include treatment of secondary progressive multi…

• FDA approval · 2025-08-18
  FDA Approved: OCREVUS ZUNOVO — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for OCREVUS ZUNOVO (ocrelizumab and hyaluronidase) from Genentech, expanding administration options …

• FDA approval · 2024-06-05
  FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Mayzent (siponimod) submitted by Novartis Pharmaceuticals Corporation.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2023-08-18
  FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)

  The FDA approved a supplemental application for Ocrevus (ocrelizumab) from Genentech, Inc. The action expands the drug's approved indication…

• FDA approval · 2022-06-21
  FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA granted approval of a supplemental application for MAYZENT (siponimod) from Novartis Pharmaceuticals Corporation.

• FDA approval · 2021-09-10
  FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Mayzent (siponimod) by Novartis Pharmaceuticals Corporation.

• FDA approval · 2020-01-10
  FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for OCREVUS (ocrelizumab) submitted by Genentech, Inc.

• FDA approval · 2019-03-26
  FDA Approved: MAYZENT — Original Application (Novartis Pharmaceuticals Corporation)

  FDA approves Mayzent (siponimod) from Novartis Pharmaceuticals Corporation in an original NDA for the treatment of relapsing forms of multip…